Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376032 · ClinicalTrials.gov registry record · NA
EndeavorOTC® Research Study in College Students
A NA study of Cognition and Attention, sponsored by Akili Interactive Labs.
- Active
- Registry status
- NA
- Development phase
- 69
- Enrollment target
- 2
- Study locations
NCT06376032: Active NA study of Cognition and Attention, sponsored by Akili Interactive Labs.
NCT06376032 is a NA study of Cognition and Attention that is active but no longer recruiting, run by Akili Interactive Labs. The registered enrollment target is 69 participants, below the 170-participant average among 35 other Cognition trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06376032, a NA study of Cognition and Attention, is active but no longer recruiting, sponsored by Akili Interactive Labs.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 69 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective of this study is to evaluate the impact of a digital therapeutic (EndeavorOTC®, also known as AKL-T01A) on clinical symptoms of executive and cognitive functioning in a real-world sample of university students. This study aims to answer whether EndeavorOTC represents a useful intervention for targeting broad cognitive and emotional health among university students.
Conditions Studied
Interventions
- DEVICE EndeavorOTC®
Study Locations (2)
New York
- Villa Maria College - Cheektowaga
Vermont
- Landmark College - Putney
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2024-01-10 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
What the registry record for NCT06376032 still lists
NCT06376032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 170-participant average among 35 other Cognition trials with a reported enrollment target (59% lower).
The record links to 3 conditions, with Cognition appearing as the primary indexed condition, and to 1 intervention - of which EndeavorOTC® is the first listed.
NCT06376032 reports a single indexed study location in New York, Vermont.
Frequently Asked Questions
What is clinical trial NCT06376032 about?
NCT06376032 is a clinical study titled "EndeavorOTC® Research Study in College Students". The objective of this study is to evaluate the impact of a digital therapeutic (EndeavorOTC®, also known as AKL-T01A) on clinical symptoms of executive and cognitive functioning in a real-world sample of university students. This study aims to answer whether EndeavorOTC represents a useful intervent...
What is the current status of trial NCT06376032?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 69 participants. The study started on 2024-01-10. Estimated completion is 2025-12-31.
What conditions does trial NCT06376032 study?
This clinical trial studies the following conditions: Cognition, Attention, University Students.
What interventions are being tested in trial NCT06376032?
The interventions under investigation include: EndeavorOTC® (DEVICE).
Who is sponsoring clinical trial NCT06376032?
This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376032 being conducted?
This trial has 2 study locations across New York, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognition
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06376032's enrollment target sits among peer trials
69 21st of 35 higher than 15 of 35 other Cognition trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognition trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults
RECRUITING · NA
-
Nutrition to Support Postoperative Recovery
RECRUITING · NA
-
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome
RECRUITING · NA
-
The Path Study: Cognitive and Inflammation Targeted Gut-brain Interventions in Alcohol; Probiotics, Alcohol, Transcutaneous Vagus Nerve Stimulation, and HIV Study
RECRUITING · NA
-
Identifying the Neural Correlates of Mental Simulation in Multi-Step Planning
RECRUITING · NA
-
Sleep Well Firefighters: An App-based Program to Improve Sleep, Cognition, and Behavioral Health in Firefighters
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI